Accumulating evidence have indicated that CRP, a nonspecific marker of inflammation, is markedly associated with the severity and prognosis of excessive inflammatory responses, such as CVD, T2DM, hemorrhagic stroke, and sepsis in COVID-19 pneumonia. This evidence concerns the gene CRP and type 2 diabetes mellitus.